Spenser Lin No Comments

Healthcare News, Deals, and Investments Update November 2nd, 2026

LECO_Weekly-Healthcare-News_11-2-2026Download

Healthcare Weekly News and Deals

  1. Ferring Pharmaceuticals agrees to acquire Insight Partners-backed Gameto for up to $1.38 billion, adding Fertilo, stem cell-based IVF platform, to its reproductive medicine portfolio. Privately held Swiss drugmaker Ferring Pharmaceuticals signed an agreement to acquire Gameto in a deal valued at up to $1.3825 billion. The companies did not say how the price splits between upfront and contingent payments. The total depends on development, regulatory and commercial milestones, and the two will operate independently until closing. Gameto has raised about $127 million since its 2020 founding from backers including Insight Partners. At the full headline value, that is a return of roughly 11x paid-in capital. Fertilo uses stem cell-derived ovarian support cells to mature eggs outside the body, which could shorten IVF cycles to about three days. It is cleared in Australia and parts of Latin America and is in U.S. Phase 3 testing. (Link)
  2. RadNet (NASDAQ: RDNT) agrees to acquire Housatonic Partners-backed ONRAD for $350 million in cash, 5 million shares and an earnout of up to $210 million, entering hospital-based teleradiology. RadNet (NASDAQ: RDNT) signed a definitive agreement on October 26 to buy ONRAD, a teleradiology and in-hospital radiology staffing provider owned by Housatonic Partners. ONRAD shareholders receive $350 million in cash and 5 million RadNet shares at closing. An earnout of up to $210 million is tied to 2027 EBITDA and is payable in cash or stock at RadNet’s election. ONRAD supports more than 225 hospital facilities in 26 states through over 130 contracted radiologists. It has grown revenue 10–20% annually with Adjusted EBITDA margins above 30%. RadNet expects $190–200 million of revenue and $60–65 million of Adjusted EBITDA in year one. ONRAD will anchor a new Radiology Professional Services segment, and closing is expected in early 2027. (Link)
  3. Merit Medical Systems (NASDAQ: MMSI) acquires the remaining ~82% of Solo Pace for about $45 million, adding TAVR temporary pacing systems to its cardiac therapies platform. Merit Medical Systems (NASDAQ: MMSI) disclosed on October 30 that it had bought all remaining equity in Minneapolis-based Solo Pace on October 13, for purchase consideration of about $45 million. The deal turns a staged strategic investment into full ownership. Between January 2023 and December 2025, Merit paid $5 million for roughly 18% of Solo Pace, an option to buy the rest on commercialization milestones, and exclusive distribution rights. Solo Pace makes the SOLO PACE CONTROL and FUSION temporary pacing systems for TAVR and other transcatheter valve procedures. (Link)
  4. Privia Health (NASDAQ: PRVA) acquires the American Choice Healthcare MSSP business from Cano Health for about $36 million, adding 36,000 attributed lives to its value-based footprint. Privia Health, based in Arlington, Virginia, is a national physician-enablement company that organizes independent practices into value-based networks. It works with more than 5,000 providers across roughly 1,300 practices in 24 states, supporting more than 5 million patients. Its ACOs, operating under Privia Care Partners, generated $233 million in shared savings in the 2024 Medicare Shared Savings Program year. American Choice Healthcare was the MSSP subsidiary of Cano Health, a Florida-based senior primary care company that went through Chapter 11 in 2024 and emerged private. The ACO joins Privia Care Partners and will care for more than 36,000 Medicare lives starting in 2027. (Link)
  5. Davion Healthcare (NASDAQ: DAVI) agrees to acquire Philadelphia’s Healthcare Stat Homecare for $13.5 million in cash and stock, the first in a planned series of acquisitions of profitable healthcare businesses. Dublin-based Davion Healthcare (NASDAQ: DAVI), a developer of non-invasive health monitoring technologies, agreed on October 27 to buy Healthcare Stat Homecare (HSH), a Philadelphia home health provider. The $13.5 million price comprises $8 million in cash and $5.5 million in Davion shares at an agreed $13 per share. HSH reported about $11.6 million of 2025 gross receipts and $1.9 million of ordinary business income, both unaudited. That implies roughly 1.2x receipts and 7x income. HSH provides skilled nursing, home health aide and rehabilitation services and is Medicare and Medicaid certified. Davion calls it the first of a year-long program to acquire profitable healthcare businesses, with completion expected by December 31, 2026. (Link)
  6. Pelthos Therapeutics (NYSE American: PTHS) to combine with Castle Creek Biosciences in an all-stock merger worth 5.2 million shares upfront, plus up to 5.8 million contingent shares and $300 million in milestones. Durham, North Carolina-based Pelthos Therapeutics (NYSE American: PTHS) agreed on October 30 to merge with Exton, Pennsylvania-based Castle Creek Biosciences. Castle Creek shareholders receive 5.2 million Pelthos shares at closing, about 32.5% of fully diluted shares. They can also receive up to 5.8 million more shares on FDA approval of D-Fi, and up to $300 million in cash milestones, including $50 million on hitting Phase 3 endpoints. They also get 80% of the proceeds from any priority review voucher. D-Fi is a redosable gene-modified cell therapy for dystrophic epidermolysis bullosa. It holds Orphan Drug, Fast Track and RMAT designations, with a continued Phase 3 study planned. Castle Creek gets two of ten board seats, and closing is expected by the end of the first quarter of 2027. (Link)
  7. Leonard Green & Partners acquires Radon Medical Imaging, a West Virginia imaging equipment service organization, from 5th Century Partners. Los Angeles-based Leonard Green & Partners bought Radon Medical Imaging from 5th Century Partners (5CP) on October 27; terms were not disclosed. Radon was founded in 1976 and is based in Charleston, West Virginia. It is an independent service organization that services, repairs and sells new and refurbished imaging equipment, including MRI, PET/CT, mammography, cath lab, C-arm and X-ray systems. Its customers are hospitals, clinics and outpatient facilities. Radon expanded from five states to 26, grew past 220 employees and completed four add-ons: Premier Imaging, Tristate Biomedical, Alpha Imaging and Majestic Medical Solutions. Leonard Green gets a scaled platform in a fragmented imaging-service market. (Link)
  8. Mainsail Partners-backed ChiroHD acquires ChiroBilling, adding native billing and revenue cycle management to its chiropractic EHR platform serving more than 2,000 clinics. Atlanta-based ChiroHD announced on October 22 that it had acquired ChiroBilling, an outsourced chiropractic billing company with a 30-person team; terms were not disclosed. Growth equity firm Mainsail Partners, which invests in bootstrapped B2B software companies, put $26 million into ChiroHD in April 2025 to fund AI-led product development and customer support. The deal adds an established revenue cycle team and its customers instead of building billing in-house. The two companies already jointly serve more than 100 clinics. ChiroBilling CEO Shannon Berg becomes president of a new ChiroBilling division. The rationale is collections leakage: chiropractors collected about 62 cents per billed dollar in 2025, down from 71 cents. (Link)
  9. Ares Management (NYSE: ARES)-backed Duly Health and Care acquires Fox Valley Imaging, an independent outpatient imaging center in Naperville, Illinois. Duly Health and Care acquired Fox Valley Imaging, according to an October 27 release; terms were not disclosed. Duly is the Downers Grove, Illinois multispecialty physician group owned by Ares Management (NYSE: ARES) and Athyrium Capital Management since 2017. Fox Valley has served Naperville for more than 30 years with MRI, MRA, CT, ultrasound, echocardiography, video fluoroscopy and X-ray. Duly plans to add mammography and DEXA at the site. That expands its outpatient imaging network in Chicago’s western suburbs and keeps more ancillary imaging volume inside its own system. Duly has more than 1,000 primary and specialty care providers across 150+ locations. The add-on extends Ares’ buy-and-build of one of the largest independent physician groups in the Midwest. (Link)
  10. Platform Partners-backed Principle Health Systems acquires mobile imaging assets in the St. Louis market, extending bedside diagnostics for long-term care facilities into Missouri and Illinois. Houston-based Principle Health Systems announced on October 30 that it had acquired select assets of an unnamed mobile diagnostic imaging company serving greater St. Louis; terms were not disclosed. Houston private investment firm Platform Partners invested in Principle in January 2023, with the founders keeping majority ownership. The deal brings imaging technologists, mobile equipment and established facility relationships. It adds bedside X-ray, ultrasound and EKG for long-term care operators in Missouri and Illinois. It follows a string of add-ons under Platform Partners: BioStat Laboratory in 2023, BioStat Imaging and Telos PGX in 2024, and Heartland Health Laboratory in 2025, plus a June 2026 asset purchase. Together they build a single-source mobile lab and imaging platform for long-term care. (Link)
  11. HealthEdge Investment Partners-backed Western Microsurgical acquires Q Surgical and Proficient Surgical, expanding its surgical microscope platform to 18 states. Denver-based Western Microsurgical (WMS), a HealthEdge Investment Partners portfolio company, announced two acquisitions on October 27; terms were not disclosed. Q Surgical serves hospitals and ASCs in Northern California and Nevada, and Proficient Surgical serves the Northeast. The owners of both sellers rolled meaningful equity into the combined company and stay active in operations. WMS is an independent manufacturer’s representative and service organization for Leica Microsystems. It also took over a Leica sales and service contract previously held by Shawnee Medical in two states. The combined business now covers 18 states. That advances HealthEdge’s plan to build a national surgical microscopy platform through partnerships with experienced regional operators. (Link)
  12. Svoboda Capital Partners partners with 120/80 Health Group, a founder-led healthcare and life sciences communications consultancy. 120/80 Health Group, founded in 2018, started as a digital health communications firm and has grown into a strategic consultancy for healthcare and life sciences. In 2024 it restructured as a holding company with two brands: 120/80, focused on digital health, and AOx3, based in Silicon Valley and New York, for companies applying technology and AI to health. Svoboda Capital Partners, founded in 1998, is a lower-middle-market private equity firm focused on professional services, industrial and commercial services, and transportation. The partnership lets 120/80 reinvest in its team and expand its service offerings. Prosper Group advised 120/80. (Link)
  13. GrowthCurve Capital makes a majority investment in TailorMed, the medication access and affordability platform spanning 950 hospitals and 4,700 clinics. TailorMed connects patients, providers, pharmacies and life sciences companies across more than 3,100 pharmacies and 6,000 support programs. It has supported 75 million patients and secured $7.4 billion in financial assistance since 2020. The capital will fund product work and expansion of its AI-powered solutions. Leerink Partners and TripleTree advised. (Link)
  14. InTandem Capital Partners completes a strategic growth investment in Atlas Health, the AI-powered patient affordability platform for hospitals and health systems. New York-based healthcare investor InTandem Capital Partners closed a growth investment in Atlas Health on October 29; terms were not disclosed. Founder and CEO Ethan Davidoff and the management team stay on as significant shareholders. Atlas was founded in 2017. It uses its agentic AI, Ava, and EHR integrations to match and enroll patients in coverage and financial assistance programs, which raises reimbursement and cuts uncompensated care for providers. InTandem’s thesis is that patient affordability is moving from a back-office task to a front-line revenue recovery tool as coverage erodes and specialty drug costs climb. The capital will fund product initiatives and expansion into specialty pharmacies. It follows InTandem’s December 2025 investment in The Phia Group. (Link)
  15. GTCR- and Heritage Group-backed Equiti acquires Lexi AI, pairing healthcare AI interpretation with its Martti human medical interpreter network. Equiti, the Sunrise, Florida-based healthcare language access company, acquired Lexi AI on October 28; terms were not disclosed. GTCR, with Heritage Group and lender Monroe Capital, bought the business from UpHealth for $180 million in November 2023. It was then combined with Voyce and rebranded as Equiti. Lexi was founded by Linh Pham and Siddharth UR and won the 2025 Harvard Business School New Venture Competition social enterprise grand prize. It provides AI interpretation in more than 35 languages, with EHR and phone integrations. Equiti’s Martti platform offers 24/7 qualified medical interpreters in 250+ languages. The add-on gives the sponsors an AI tier to sell alongside human interpretation. (Link)
  16. The Riverside Company adds CSB Nutrition to its Western Botanicals / WB Blends supplements manufacturing platform, expanding capsule and powder capacity. Western Botanicals is a vitamins, minerals, and supplements contract manufacturer founded in 1996. It has more than 200 employees and over 200,000 square feet across three facilities, and its products are sold through channels including Walmart, Amazon, Target, Vitamin Shoppe, and Costco. The Riverside Company acquired it in February 2026 and later added Yellow Emperor, a liquid specialist. CSB Nutrition, also based in Spanish Fork and founded in 2001 by Al Call, Craig Shields, and Jeff Bancroft, is a full-service VMS CDMO with roughly 60 to 200 employees and a cGMP, NSF-certified, FDA-registered facility of more than 100,000 square feet. It serves major VMS brands and also works in sports nutrition, personal care, and pet care. Together with WB Blends and Yellow Emperor, the platform now covers capsules, powders, and liquids in one place, including stick packs and gusseted bags. Riverside has made more than 40 platform investments under its health, longevity, and flavor thesis. (Link)
  17. US WorldMeds acquires Orbus Therapeutics, backed by Longitude Capital, H.I.G. HealthBridge, Abingworth, Adams Street Partners and Agent Capital, to advance eflornithine in recurrent Grade 3 astrocytoma. Louisville, Kentucky-based US WorldMeds acquired Menlo Park, California-based Orbus Therapeutics on October 27. It made an undisclosed upfront payment, with development, regulatory and sales milestones plus tiered U.S. royalties to follow. That gives Orbus’s investors an exit with continued upside: Longitude Capital, H.I.G. HealthBridge, Abingworth, Adams Street Partners and Agent Capital. In the Phase 3 STELLAR trial, Orbus’s oral eflornithine missed its primary overall-survival endpoint across all patients. However, a subset defined before unblinding, patients with IDH-mutant Grade 3 astrocytoma, showed median overall survival of 34.9 months versus 23.5 months. The program holds FDA Breakthrough Therapy designation. US WorldMeds already markets eflornithine as IWILFIN for high-risk neuroblastoma and plans to discuss a path forward with the FDA. (Link)
  18. Water Street Healthcare Partners- and JLL Partners-backed EVERSANA acquires Estima Scientific, adding AI-powered health economics and outcomes research tools to its life sciences commercialization platform. Estima, a London firm founded in 2019, pairs specialist consulting with proprietary generative-AI applications for economic modeling, systematic literature reviews and network meta-analysis. Its tools have been used by large pharma and by the U.K.’s NICE. EVERSANA will fold the capability into its market access and value-and-evidence offerings; co-founders Tim Reason and Andy Gimblett join the EVERSANA team. (Link)
  19. Azenta (NASDAQ: AZTA) acquires SynPlexity and signs an exclusive license with Elegen to expand its GENEWIZ gene synthesis business. Burlington, Massachusetts-based Azenta (NASDAQ: AZTA) announced two deals on October 30; terms were not disclosed. It acquired SynPlexity, a synthetic biology company that makes high-throughput pooled gene libraries, and signed an exclusive license for Elegen’s cell-free DNA manufacturing platform. SynPlexity’s pooled assembly technology produces thousands of full-length gene variants in a single library. That lets researchers build and test large numbers of candidates, including AI-generated designs. Elegen’s platform aims for higher DNA quality, faster delivery and compact production lines that can be sited near customers. Both strengthen GENEWIZ, Azenta’s sequencing and gene synthesis unit, in synthetic biology, protein engineering and AI-enabled drug discovery. Azenta will give more detail on its fiscal Q4 2026 earnings call. (Link)
  20. Peak Rock Capital-backed HuFriedyGroup signs an agreement to acquire the dental business of Italy’s Mectron, adding piezoelectric surgery, ultrasonic scaling and air-polishing systems to its global dental portfolio. HuFriedyGroup is a global maker of dental instruments, infection prevention products, and instrument management systems. Founded in 1908, it has roughly 1,500 employees, more than 10,000 products, and distribution in about 100 countries under brands including Hu-Friedy, Crosstex, Omnia, Accutron, and SS White. Peak Rock acquired it from Steris in 2024 for roughly $788 million. Mectron, founded in 1979 in Carasco, Italy, pioneered piezoelectric bone surgery with the launch of PIEZOSURGERY in 2001. It has about 250 employees and operates in more than 70 countries. The deal covers Mectron’s dental operations in Italy, the non-medical activities of its German subsidiary, and the dental activities of Piezosurgery Inc. in Columbus, Ohio. Mectron keeps its medical business. Manufacturing stays in Carasco under a multi-year supply agreement, so HuFriedyGroup gains the technology and commercial reach without disrupting production. (Link)
  21. NeckWise acquires Western Carolina Chiropractic, adding an Asheville practice to its upper cervical chiropractic network. NeckWise is a growing multi-state network of upper cervical chiropractic offices founded in 2024 by Dr. Drew Hall, Dr. Matt Morris, and Dr. Rusty Lavender. The group focuses exclusively on the atlas (C1) and axis (C2) vertebrae, using in-office cone beam CT imaging and gentle, no-twist adjustments rather than traditional full-spine manipulation. It has offices across Florida, including the Tampa Bay area, Sarasota, Fort Myers, and Riverview, and in the Salt Lake City area of Utah. The Asheville practice’s Dr. Michael DiNunzio stays on. The location will add in-office 3D cone beam imaging, consistent with NeckWise’s standard across its network. (Link)
  22. Baystate Health integrates Baystate Mercy Hospital and its affiliates into its system, adding a Springfield hospital and 45 medical group entities. Baystate Health is a not-for-profit integrated system serving more than 800,000 people across western Massachusetts. It has roughly 13,000 employees, five hospitals, and more than 900 beds, with roots dating to the founding of Springfield Hospital in 1883. Baystate Medical Center is a 780-bed academic medical center and a teaching site of UMass Chan Medical School. Mercy Medical Center, previously part of Trinity Health of New England, faced financial pressures that put its long-term viability at risk. The $300 million integration covers Baystate Mercy and its joint venture affiliates, along with 45 medical group entities. Emergency department staffing moves to Baystate’s board-certified faculty, and the Sister Caritas Cancer Center joins Baystate’s cancer program. The systems are also unifying on an Oracle Health EHR. (Link)
  23. PsychPlus acquires California-based Precision Psychiatric Services, adding more than 100 psychiatrists and hospital partnerships to its technology-enabled mental health platform. Houston-based PsychPlus announced on October 23 that it had acquired Precision Psychiatric Services, a physician-led psychiatric group founded in 2018; terms were not disclosed. Precision brings more than 100 psychiatrists and hospital partnerships across California. Its hybrid in-person and telepsychiatry model covers emergency departments, inpatient units, consultation-liaison, outpatient and addiction settings. The deal follows PsychPlus’s acquisition of digital therapeutics developer Koa Health. Together they form a roll-up spanning prevention through hospital-based care. PsychPlus already works with more than 200 hospital systems and reports reach of over 6 million people. (Link)

Venture Deals and Other

  1. Bristol Myers Squibb (NYSE: BMY) leads Pathos AI’s $237 million Series E at a roughly $3 billion post-money valuation, with existing investors participating. New York-based Pathos AI closed a $237 million Series E on October 23 at a post-money valuation of about $3 billion. Bristol Myers Squibb (NYSE: BMY) led and existing investors participated. BMS’s check comes with a strategic deal: non-exclusive access to Pathos’s Foundry agentic AI platform across its R&D portfolio, and three-year exclusive rights in neuroscience. Pathos will also license a neurological-disease dataset from Tempus AI (NASDAQ: TEM) under a five-year, $55 million agreement. Proceeds will scale Foundry and advance four clinical oncology assets. The priority is JSKN-016, a TROP2/HER3 bispecific ADC heading toward registrational studies. The others are pocenbrodib, AstraZeneca (NASDAQ: AZN)-partnered AZD4241 and MET inhibitor DO-2. (Link)
  2. Avego leads Opentrons Labworks’ $40 million Series E, with BroadOak Capital Partners participating, to scale lab robotics and AI-driven autonomous science. Opentrons Labworks raised a $40 million Series E on October 30. Healthcare investor Avego led, with additional investment from BroadOak Capital Partners; valuation was not disclosed. Opentrons has deployed more than 11,000 lab automation robots in over 80 countries to academic groups, diagnostic labs and global pharma companies. Avego’s thesis is that drug developers and AI companies are moving to automated workflows that generate machine-usable data, and that these workflows will converge on Opentrons’ platform. Proceeds will fund AI-driven experiment execution, faster protocol development, broader instrument capabilities, deeper integration with other lab-automation tools, and expansion into new markets. Earlier this year Opentrons began using Nvidia (NASDAQ: NVDA) Isaac and Cosmos to generate physical-AI training data. (Link)
  3. Threshold Ventures leads Vera Health’s $28.5 million Series A, with Mantis VC, SV Angel, Y Combinator and Gradient participating, bringing total funding to $32 million. San Francisco-based Vera Health announced a $28.5 million Series A on October 27 led by Threshold Ventures. New investors Mantis VC and SV Angel joined, and existing backers Y Combinator and Gradient tripled down, bringing total funding to $32 million. The investor case is capital efficiency. With 12 employees, Vera’s evidence-graded clinical decision support tool grew from a few thousand to more than 800,000 clinicians in 190 countries in a year, mostly through word of mouth. It has been the world’s most downloaded clinical app every month since June and reaches about one in four physicians in Spain and Italy. Funds will build evidence infrastructure, enter new markets and deepen medical-society partnerships such as ACEP. (Link)
  4. Metis MedTech leads StimCardio’s oversubscribed $30 million Series A, with Catalyst Health Ventures and corporate strategic investors participating, to fund a pivotal trial of its wearable atrial fibrillation therapy. StimCardio closed an oversubscribed $30 million Series A on October 29. It was led by Metis MedTech, the family office of John Slump, with Catalyst Health Ventures, several unnamed corporate strategic investors and new and existing backers participating. Slump’s prior exits include Farapulse and Atraverse Medical, more than $1.25 billion in combined deal value. He and Catalyst managing partner Joshua Phillips sit on the board. The round funds the NeuroPulse 2 pivotal study and an FDA De Novo submission for Rhyvive. Rhyvive is a wrist-worn nerve stimulator designed to reduce atrial fibrillation recurrence after catheter ablation, where 30–40% of patients relapse. It follows positive sham-controlled NeuroPulse 1 data published in Heart Rhythm. (Link)
  5. Valtruis leads Midstream Health’s $20 million Series A, with Andreessen Horowitz, Foundry and CommonSpirit Ventures participating, to scale AI financial operations for health systems. San Francisco-based Midstream Health raised a $20 million Series A on October 29 led by Valtruis. Andreessen Horowitz, Foundry and CommonSpirit Ventures continued to participate, bringing total funding to $29.2 million. Midstream’s AI agents check health-system contracts, claims, purchasing and pharmacy data against live transactions. They recover missed rebates, unenforced pricing terms and payer underpayments. Its customers represent more than $100 billion of annual operating expenses and over 250 hospitals. They include CommonSpirit Health, Mount Sinai and Houston Methodist, plus new clients Fairview Health Services and Keck Medicine of USC. Midstream has found 1,500+ recovery opportunities this year and is on pace for $100 million of client savings by year-end. (Link)
  6. Headline leads ClarityCare’s oversubscribed $16.5 million Series A, with Arthur Ventures, FJ Labs, Maverick, firstminute, Top Harvest Capital and Transpose Platform participating. ClarityCare announced an oversubscribed $16.5 million Series A on October 26, bringing total funding to nearly $20 million. Headline led, with new investors Arthur Ventures and FJ Labs and existing backers Maverick, firstminute, Top Harvest Capital and Transpose Platform. ClarityCare is an AI services company for health plans. Its Electra agent reviews authorization requests against clinical guidelines and member benefits and keeps a full audit trail. It can approve or escalate a request but never issues a denial, which reduces exposure as AI-driven denials draw scrutiny. Electra now handles requests end to end, from fax intake through case creation to outbound letters. The funding will go to hiring, new products and expansion into the government sector. (Link)
  7. Deerfield Management leads Setara Biosciences’ $90 million Series A, with Canaan, Droia Ventures, EcoR1, Euclidean Capital, Regeneron Ventures and Jazz Pharmaceuticals participating. Setara was formed after Jazz acquired Actio Biosciences for its lead epilepsy program. The new company takes the rest of Actio’s genetics-driven pipeline, led by the TRPV4 inhibitor STAR-0871 (formerly ABS-0871) for Charcot-Marie-Tooth type 2C and overactive bladder. David Goldstein, former Actio CEO, leads Setara. (Link)
  8. Camino Partners, founded by KIND Snacks founder Daniel Lubetzky, invests $62 million in Intake Breathing, the maker of a magnetic nasal dilator system. This is Intake’s first institutional capital and Camino’s largest investment. The Santa Barbara company has sold more than 100 million pairs of its breathing tabs and is approaching $100 million in annual revenue. Capital goes to team growth, retail expansion and scaling the consumer wellness brand. (Link)
  9. Viatris (NASDAQ: VTRS) launches its $36.50-per-share cash tender offer for Pacira BioSciences (NASDAQ: PCRX), valuing the non-opioid pain management company at about $1.46 billion. Viatris (NASDAQ: VTRS) started a cash tender offer on October 30, through its subsidiary Peach Purchaser Sub, for all outstanding shares of Pacira BioSciences (NASDAQ: PCRX). The price is $36.50 per share, about $1.46 billion in equity value. The offer follows a merger agreement signed October 8, and Pacira’s board unanimously recommends that shareholders tender. It expires at the end of November 16 unless extended. Closing requires a majority of shares to be tendered and antitrust clearance; there is no financing condition. A second-step merger under Delaware Section 251(h) will follow without a shareholder vote. The deal adds Pacira’s non-opioid pain franchise, led by EXPAREL, to Viatris’ branded portfolio. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update July 27th, 2026

LECO_Weekly-Healthcare-News_7-27-2026Download
  1. Longshore Capital Partners entered a strategic growth partnership with revenue cycle management provider Prochant. Chicago-based Longshore Capital Partners, a lower middle-market private equity firm that takes control positions in North American services businesses with $5 million to $15 million of EBITDA, invested in Prochant, a Charlotte, North Carolina technology-enabled RCM provider serving home medical equipment, DME, infusion and specialty pharmacy operators. Terms were undisclosed. Capital will fund technology, analytics, AI and automation investment, service capacity expansion, new revenue cycle product development and talent acquisition, alongside acquisitions in core markets. Longshore is backing an existing management team under CEO Joey Graham, preserving leadership and culture while accelerating investment in a recurring-revenue outsourced services model. (Link)
  2. SkyKnight Capital, L.P. agreed to acquire a controlling position in Apex Infusion from FFL Partners, which retains a minority stake alongside the clinician-led management team. SkyKnight Capital, a San Francisco private equity firm, signed a definitive agreement to partner with Apex Infusion, a Signal Hill, California omnichannel infusion services provider founded in 2006. FFL Partners, which completed its investment in 2024, remains a minority shareholder, and Apex’s clinician-led management retains significant ownership and continues to lead the business. Apex delivers therapy through a home infusion nursing network and roughly 40 ambulatory infusion suites. SkyKnight intends to fund new market entry, health system and payor partnerships, and technology-enabled access initiatives across a site-of-care shift thesis. (Link)
  3. Winterbird Partners made a growth investment in Minneapolis-based Microsoft services partner Emergent Software. Winterbird Partners invested in Emergent Software, a Minneapolis, Minnesota Microsoft services partner specializing in data modernization, AI deployment, cloud transformation, application development and managed services. Deal value was not disclosed. Led by CEO Jamie Anderson, Emergent manages solutions across the Microsoft ecosystem including Fabric, Azure, Copilot, Foundry and modern data platforms. Proceeds will fund headcount expansion, additional service capabilities and entry into new geographies. For Winterbird, the transaction is a bet on the durability of enterprise AI and data-platform implementation, backing a founder-led services firm against a single hyperscaler ecosystem rather than horizontal consultancy model. (Link)
  4. Healthcare technology platform Focus entered a definitive agreement to acquire Plano, Texas-based managed technology services company GuideIT. Focus, a Chicago-headquartered healthcare technology services company, agreed to acquire GuideIT, a nationally recognized managed technology services provider offering managed IT, cybersecurity, cloud integration, IT and clinical service desk, and medical data services. Terms were undisclosed; GuideIT will operate as GuideIT, A Focus Company. Focus supports more than 100 electronic health record and practice management systems and is consolidating fragmented healthcare vendor relationships into a single accountable partner. GuideIT CEO and board member Russell Freeman described a deliberate partner selection process. The acquisition scales Focus’s Unified Healthcare Platform thesis through capability breadth rather than geographic density. (Link)
  5. Knox Lane completed its $437 million take-private acquisition of Cross Country Healthcare, Inc. (formerly NASD: CCRN), concurrently selling the locums division to portfolio company All Star Healthcare Solutions. Growth-oriented investment firm Knox Lane closed its all-cash acquisition of Cross Country Healthcare at $13.25 per share, valuing the technology-enabled workforce solutions company at roughly $437 million and ending its NASD listing. The deal follows a terminated agreement with Aya Healthcare. Knox Lane simultaneously moved Cross Country’s locum tenens division into All Star Healthcare Solutions, an existing portfolio company, creating immediate platform consolidation. Managing Partner John Bailey and Partner Shamik Patel cited the company’s position at the intersection of workforce services and technology. Joel Tremblay, formerly of Medical Solutions, was installed as CEO, succeeding co-founder Kevin Clark. (Link)
  6. Care Career acquired MAS Medical Staffing, completing its first acquisition phase and lifting consolidated annual revenue beyond $150 million. Woodbridge, New Jersey-based Care Career, a healthcare workforce technology organization led by CEO Siva Konatham, acquired Manchester, New Hampshire-based MAS Medical Staffing, including its travel, allied and per diem operations and technology assets. Financial terms were undisclosed. This is Care Career’s seventh acquisition in 24 months, following IDR Healthcare in February 2026, Source Medical Staffing in October 2025, and four firms in May 2025. The completed first round now exceeds $150 million of annual revenue, with signed LOIs expected to close in Q3 2026 pushing consolidated revenue past a quarter billion by year-end, aided by MAS’s Maestra workforce platform. (Link)
  7. Equality Asset Management-backed Mindoula acquired Valera Health and Janus Healthcare Partners in a double transaction expanding its whole-person care enablement platform. Mindoula, the Silver Spring, Maryland behavioral health company backed by Equality Asset Management, simultaneously acquired New York-based virtual mental health provider Valera Health and Duxbury, Massachusetts psychiatric collaborative care provider Janus Healthcare Partners. Terms were undisclosed. These are Mindoula’s third and fourth acquisitions since its 2013 founding, following Care at Hand and 180 Health Partners. Valera contributes more than 300 multi-state behavioral providers and specialization in suicide risk reduction, DBT and serious mental illness; Valera had itself raised $74.3 million and acquired Vita Health in 2025. Janus adds psychiatry CoCM capability, positioning Mindoula for value-based contracts with payers and health systems. (Link)
  8. Beacon Behavioral Partners entered Ohio and Michigan through a partnership with Ohio- and Michigan-based Pure Psychiatry, adding a 17-location outpatient platform. Plano, Texas-based Beacon Behavioral Partners, a growing network of independent psychiatric practices, acquired Pure Psychiatry, establishing its first presence in Ohio and Michigan and marking one of its largest expansions to date. Financial terms were undisclosed. Pure Psychiatry, led by founders Taylor Hennrick, PA-C, Sarang Patel, PA-C and Dr. Rakesh Amin, provides psychiatric care across all age groups including medication management for anxiety, depression, ADHD and bipolar disorder. Beacon will supply operational, administrative and strategic support to fund de novo clinic openings and provider recruitment. The deal follows Beacon’s appointment of Rob Jardeleza as CEO roughly a week earlier. (Link)
  9. Truehelm-backed Wildflower Health acquired digital pelvic floor platform Every Mother, marking its entry into direct-to-consumer women’s health. Wildflower Health, the San Francisco tech-enabled women’s health company backed by Truehelm, acquired Every Mother, a clinically validated core and pelvic floor therapy platform founded by Allison Rapaport. Terms were undisclosed. Wildflower operates enterprise infrastructure connecting commercial health plans, risk-bearing provider groups and patients across all 50 states, supporting thousands of women’s health providers. Every Mother contributes HSA/FSA-eligible on-demand exercise programs addressing diastasis recti, urinary incontinence, pelvic organ prolapse and pelvic pain. Strategically, the acquisition adds a consumer subscription revenue channel to an enterprise contracting model and extends patient relationships beyond the traditional six-to-twelve-week postpartum drop-off. (Link)
  10. DuneGlass Capital-backed Aviva Aesthetics expanded into Ohio through a partnership with Avon, Ohio-based Vitality Health. Aviva Aesthetics, the Chicago-based entrepreneur-owned medical aesthetics platform launched in 2024 with healthcare services independent sponsor DuneGlass Capital, partnered with Vitality Health, a medical aesthetics and wellness practice in Avon, Ohio founded in 2014 by Alana Mercer, PA-C. Terms were undisclosed. This is Aviva’s eighth partnership of 2026 and its first Ohio location, deepening Midwest presence. Vitality Health provides injectables, laser treatments, skin rejuvenation, weight management and hormone optimization. Aviva’s Entrepreneur Equity structure explicitly positions against traditional private equity roll-ups, allowing founders to retain full equity and control while accessing scale economics and back-office support. (Link)
  11. PE-backed Premier Care Dental Management acquired cosmetic dentistry practice Brookline Smile Artists in Massachusetts. Premier Care Dental Management, the New Hyde Park, New York dental clinical organization operating under the Dental365 brand and backed by The Jordan Company, added Brookline, Massachusetts-based Brookline Smile Artists to its network. Terms were undisclosed. PCDM supports practices across New York, Connecticut, New Jersey, Pennsylvania, Ohio, New Hampshire, Massachusetts and Rhode Island, and has pursued an acquisition-led growth cadence including multiple Ohio additions earlier in 2026. The tuck-in extends the sponsor-backed platform further into higher-margin cosmetic dentistry, a service line with meaningful cash-pay mix, while continuing the roll-up strategy aimed at retiring and scaling-back owner-dentists across the Northeast. (Link)
  12. Shore Capital Partners-backed Innovate 32 partnered with Houston-based Post Oak Dental, expanding its Texas dental support organization footprint. Innovate 32, the Nashville-based dental services organization formed by Chicago lower middle-market private equity firm Shore Capital Partners, closed a partnership with Post Oak Dental, an established Houston, Texas practice. Terms were undisclosed. Under CEO Josh Johnson and a board combining dentists, multi-site healthcare operators and private equity executives, Innovate 32 has assembled a network across Texas, Tennessee, Florida and the Mid-Atlantic since its 2024 founding. Post Oak Dental retains its clinical focus while gaining management infrastructure. For Shore, the affiliation continues a disciplined buy-and-build in general dentistry, prioritizing clinician alignment and local leadership over transactional roll-up. (Link)
  13. Dentalcorp entered the U.S. market with the acquisition of Florida-based Northstar Dental Partners. Toronto-based Dentalcorp, one of the largest dental support organizations in North America, acquired Northstar Dental Partners, a Boca Raton-headquartered group supporting 21 dental practices across South Florida, the Treasure Coast, Southwest Florida and Central Florida. Founder and CEO Dr. Jordan Tomalty retains an ownership stake and will remain instrumental to continued growth. Combined with Dentalcorp’s Canadian network, the partnership brings the total to over 650 supported practices. (Link)
  14. vybe urgent care acquired Liberty Urgent Care’s Horsham and Hatfield centers, supported by growth-oriented debt financing from Live Oak Bank. vybe urgent care, the leading independent urgent care operator in greater Philadelphia, acquired Liberty Urgent Care’s two Montgomery County, Pennsylvania centers, expanding its network from 16 to 18 sites. Terms were undisclosed. The transaction was funded through a recent growth-oriented refinancing completed with Live Oak Bank, which vybe intends to draw on for further acquisitions and de novo development. Liberty founder Erik Soiferman, D.O. joins as Vice President of Occupational Medicine Services, strengthening vybe’s occupational health and workers’ compensation capabilities. The debt-funded structure allows the independent operator to consolidate a fragmented regional market without an equity sponsor. (Link)
  15. Ares Management Corporation (NYSE: ARES) and Rubicon Founders-backed US Heart & Vascular acquired Tennessee physician-owned practice Apex Vascular and its outpatient center. US Heart & Vascular, the Nashville-area cardiovascular support services platform backed by funds managed by the Private Equity Group of Ares Management (NYSE: ARES) alongside Rubicon Founders, acquired Apex Vascular and Apex Vascular Outpatient Center. Terms were undisclosed. Headquartered in Lenoir City, Tennessee, Apex has served East Tennessee for nearly two decades across Knoxville, Crossville, Harrogate, Decatur, Sevierville and Oak Ridge, treating peripheral artery disease, varicose veins, carotid artery disease and dialysis access. Founder Christopher Pollock, MD cited access to resources for regional expansion. The tuck-in deepens USHV’s density in a specialty prized for recurring outpatient procedure volume. (Link)
  16. Paradigm Oral Health bought back BlackRock, Inc.’s (NYSE: BLK) Long Term Private Capital stake in a surgeon-led transaction backed by a Warburg Pincus-led group including Goldman Sachs (NYSE: GS) Alternatives and Sixth Street. Lincoln, Nebraska-based Paradigm Oral Health repurchased BlackRock Long Term Private Capital’s ownership stake, returning majority control to its surgeons and management. The buyback is funded by a significant investment led by Warburg Pincus, a private partnership since 1966, in partnership with Goldman Sachs (NYSE: GS) Alternatives and Sixth Street. Terms were undisclosed. Founded in 2018 by David Rallis, DDS, MD, Paradigm operates an oral surgery and digital dentistry platform built to attract and retain surgeons. The structure is notable for reversing conventional sponsor control: incoming capital supports clinician majority ownership, technology investment, advanced training and de novo clinic expansion. (Link)
  17. Groups Recover Together acquired Better Life Partners in its first-ever acquisition, doubling its New England patient volume.Burlington, Massachusetts-based Groups Recover Together, the value-based opioid use disorder treatment provider backed by Oak HC/FT, Bessemer Venture Partners, Transformation Capital, RRE Ventures, Optum Ventures and Kaiser Permanente Ventures, acquired Better Life Partners in a transaction that closed March 31. Financial terms were undisclosed. Better Life Partners, founded in Vermont in 2018 and backed by aMoon, Alumni Ventures, F-Prime Capital, Maverick Ventures and .406 Ventures, had raised $26.5 million in a 2023 Series B but experienced financial distress. CEO Cooper Zelnick highlighted mental health and virtual primary care capabilities the company intends to scale nationally beyond New England. (Link)
  18. Ohio-based Cardinal Health (NYSE: CAH) agreed to acquire the Diabetes Health business of AdaptHealth Corp. (NASD: AHCO) and, in its entirety, NMS Capital-backed Strive Medical for approximately $360 million in cash. Cardinal Health (NYSE: CAH), headquartered in Dublin, Ohio, deployed roughly $360 million of cash across two definitive agreements to scale its at-Home Solutions platform, subject to working capital adjustments. The AdaptHealth (NASD: AHCO) unit serves over 225,000 patients annually through a centralized mail-order CGM model, while NMS Capital portfolio company Strive Medical adds urology, wound care, ostomy and incontinence supply distribution to 20,000-plus patients. Both transactions build on Cardinal’s Advanced lDiabetes Supply acquisition and are expected to be accretive to non-GAAP EPS within twelve months of close, extending the Ohio distributor’s consolidation of fragmented direct-to-patient supply channels. (Link)
  19. Surgery Partners, Inc. (NASD: SGRY) agreed to sell its ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health for approximately $795 million. Surgery Partners (NASD: SGRY), the Brentwood, Tennessee short-stay surgical facility operator, placed into escrow signature pages to sell its Idaho Falls hospital interests to existing partner Intermountain Health, a Utah-based nonprofit system of 34 hospitals and roughly 400 clinics. The transaction values the combined facilities at approximately $1.15 billion, with total consideration to Surgery Partners of about $795 million before purchase price adjustments. Physician ownership of Mountain View Hospital is unchanged. CEO Eric Evans framed the divestiture as portfolio optimization, refocusing capital toward ambulatory surgery centers. The company reaffirmed 2026 revenue guidance of $3.35–$3.45 billion excluding transaction impact. (Link)
  20. Gentherm Incorporated (NASD: THRM) acquired Ohio-based Innovative Medical Equipment, LLC, maker of the ThermaZone thermal therapy device. Gentherm (NASD: THRM), the Novi, Michigan thermal management and pneumatic comfort technology leader, acquired Innovative Medical Equipment, a Cleveland-area, Ohio provider of the ThermaZone non-opioid hot-and-cold thermal therapy system. Terms were undisclosed. Founder and President Brad Pulver framed Gentherm’s scale and global operating footprint as the growth enabler for the Ohio business. Management expects revenue synergies from cross-selling ThermaZone through Gentherm’s expanded healthcare customer channels. Announced alongside record Q2 2026 revenue of $416 million, raised full-year guidance and a new $400 million repurchase authorization, the deal advances Gentherm’s strategic pivot toward higher-margin medical adjacencies. (Link)
  21. RS2 Healthcare Partners, the Boston-based private equity firm formerly known as Riverside Partners, completed an investment in KMM Group, a Hatboro, Pennsylvania-based vertically integrated precision contract manufacturer serving the medical device industry. RS2 Healthcare Partners, founded in 1989 and rebranded from Riverside Partners in May 2026 to formalize an exclusive lower-middle-market healthcare strategy, closed an investment in KMM Group. Terms and stake size were undisclosed. The firm has raised $1.6 billion in total capital commitments since inception and concentrates on pharma services, medical device contract manufacturing and technology-enabled healthcare, supported by healthcare, clinical and AI advisory boards. KMM produces complex, tight-tolerance components for failure-intolerant end markets. J. Mark King joins as President and CEO, while co-founders John Shegda and Eric Wilhelm move to Chief Technology Officer and Executive Vice President, Business Transformation, preserving customer and employee continuity under sponsor ownership. (Link)
  22. Eurofins Scientific (EUFI.PA) agreed to acquire Element Materials Technology’s Life Sciences Testing Services business in North America for an enterprise value of $400 million. Eurofins Scientific, a global leader in bioanalytical testing, reached agreement with Element Materials Technology to acquire its North America Life Sciences Testing Services business, encompassing biopharma product testing, environmental testing and food testing across a network of 27 laboratories and facilities employing approximately 750 FTEs. The business is expected to generate over $150 million in 2026 revenues with profitability in line with the Eurofins Group average. The transaction expands Eurofins’ geographic footprint in key U.S. and Canadian regions where it has been underrepresented and is expected to close in Q4 2026 subject to customary regulatory approvals. (Link)
  23. Repligen Corporation (NASD: RGEN) agreed to acquire BioLife Solutions, Inc. (NASD: BLFS) for a total enterprise value of approximately $1.5 billion. Repligen will acquire BioLife in a cash-and-stock transaction valued at $31.00 per BioLife share ($11.25 cash plus 0.1442 shares of Repligen common stock), representing a 24% premium to the 90-day VWAP. The deal adds BioLife’s market-leading biopreservation media platform (including CryoStor) and cell-processing tools that support 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based trials. The transaction is expected to be accretive to growth, margins and adjusted EPS (at least 5 cents in year one and 25 cents in year two) with $20–30 million of synergies; closing is targeted for Q4 2026. (Link)
  24. Nordic Capital agreed to sell life sciences software platform ArisGlobal to Dassault Systèmes (Euronext Paris: DSY) for up to $2 billion, marking a full exit for the Swedish sponsor. Nordic Capital, which manages approximately €39 billion, is exiting ArisGlobal entirely in a sale to Dassault Systèmes (Euronext Paris: DSY) reported at $1.8 billion cash plus a $200 million earnout. Nordic first invested in 2019 via its ninth fund at a reported $700 million enterprise value and added to its stake in 2021. Under Nordic’s ownership the Waltham, Massachusetts company converted to SaaS, completed two bolt-ons and is expected to generate roughly $175 million of 2026 revenue, processing 12 million safety cases annually for 200-plus customers. Closing is expected in the second half of 2026. (Link)
  25. Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) entered a definitive agreement to acquire certain cannabis cultivation, manufacturing and retail assets of The Cannabist Company Holdings Inc. across five markets for up to $35 million. Vireo Growth, through subsidiary Vireo Health of Arcadia, agreed to acquire selected operations from Cannabist subsidiaries in Colorado, Illinois, Massachusetts, New Jersey and West Virginia for total consideration of up to US$35 million (up to US$18.75 million cash at closing plus up to US$16.25 million in seller notes), subject to adjustments and regulatory approvals. The staged transaction is expected to add up to 25 dispensaries plus cultivation and production assets, deepening Vireo’s Colorado presence and adding four new states. Closing is targeted through 2026 into 2027 amid Cannabist’s CCAA and Chapter 15 proceedings. (Link)
  26. Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) agreed to acquire Planet 13 Holdings Inc. (CSE: PLTH; OTCQX: PLNH) in an all-share merger. Vireo Growth entered a definitive merger agreement to acquire all outstanding equity of Planet 13, with each Planet 13 share converting into 0.015383618 of a Vireo subordinate voting share (16.6% premium to the 20-day VWAP and 24% premium to the closing price as of July 24, 2026). The transaction deepens Vireo’s Nevada and Florida footprints (adding the flagship Las Vegas superstore, additional dispensaries, cultivation/production capacity and licenses) and adds a Waukegan, Illinois dispensary. On a pro forma basis with prior announced deals, Vireo expects to operate approximately 265 dispensaries across 15 states. Closing is subject to stockholder, regulatory and listing approvals. (Link)
  27. First Choice Healthcare Solutions, Inc. (OTCQB: FCHS) and Westin Acquisition Corp. (NASD: WSTN) announced a definitive business combination agreement to create a publicly traded healthcare and wellness company. The transaction values First Choice at a pro forma enterprise value of approximately $650 million and is expected to accelerate its strategic rebrand to Wellgevity 360, a platform focused on longevity, preventative care and personalized biology-driven solutions. Westin will domesticate and the combined company is expected to trade on NASD. Closing is targeted for Q4 2026 subject to customary approvals and conditions. (Link)
  28. Avanos Medical, Inc. (NYSE: AVNS) stockholders approved the company’s $25.00-per-share take-private by American Industrial Partners, valuing the medtech at roughly $1.272 billion. Avanos Medical (NYSE: AVNS) shareholders voted overwhelmingly in favor of the acquisition by affiliates of funds advised by American Industrial Partners, with approximately 99.75% of shares voted supporting the merger, representing about 74.96% of shares outstanding as of the June 18 record date. Holders receive $25.00 per share in cash, an enterprise value near $1.272 billion and a 72.1% premium to the pre-announcement close, plus an 82.8% premium to the 30-day VWAP. All regulatory approvals had been obtained, with closing expected no later than July 27, 2026. The operationally focused industrials investor takes Avanos private, delisting from the NYSE. (Link)
  29. Royalty Pharma plc (NASD: RPRX) acquired a portion of Neurimmune’s royalty interest in cliramitug for up to $425 million. Royalty Pharma (NASD: RPRX) committed up to $425 million to Zurich-based Neurimmune in exchange for a 3% to 4% royalty on worldwide net sales of cliramitug, an investigational anti-amyloid antibody for ATTR cardiomyopathy. The structure front-loads $125 million upfront, with a further $125 million payable in Q1 2027 and $175 million tied to clinical and regulatory milestones. Cliramitug is licensed globally to Alexion, AstraZeneca Rare Disease, which is running the Phase 3 DepleTTR-CM trial. For Royalty Pharma, the transaction buys exposure to the rapidly growing ATTR-CM market; for Neurimmune, it is non-dilutive capital funding its internal pipeline. (Link)
  30. Aurobindo Pharma Limited (NSE: AUROPHARMA; BSE: 524804), through wholly owned subsidiary Apitoria Pharma Private Limited, agreed to acquire 80% ownership control of A1 Biochem Labs (India) Private Limited and A1 Biochem Labs LLC, USA at a $17 million enterprise value. Aurobindo Pharma (NSE: AUROPHARMA; BSE: 524804) is deploying $13.6 million in cash through Apitoria Pharma for an 80% interest in A1 Biochem Group’s contract research business, struck at a $17 million enterprise value on a debt-free, cash-free basis, subject to closing adjustments. The existing promoter retains 20%, and A1 Biochem Labs (India) will absorb A1 Biochem Labs LLC and the CRO business of A1 Biochem Research (India). The target posted FY26 turnover of ₹1,024.42 million and EBITDA of ₹465.46 million — a 45% margin — across Wilmington and Hyderabad labs with 90-plus scientists. Aurobindo is building an integrated CRDMO platform across the API value chain; closing is expected in 90 to 120 days. (Link)
  31. Scancell Holdings plc (AIM: SCLP) and Neuphoria Therapeutics Inc. (NASD: NEUP) announced an all-share merger agreement and associated financing. Scancell will acquire Neuphoria in an all-share transaction; the combined company will operate as Scancell, list on NASD (in addition to AIM) and advance a pipeline of targeted, off-the-shelf active immunotherapies, led by iSCIB1+ in advanced melanoma. Existing Scancell shareholders are expected to own approximately 85.5% and Neuphoria shareholders 14.5% on a pro forma basis (before financing). Concurrent financing of up to $89 million (equity and debt) is intended to fund the global registrational Phase 3 trial. Closing is targeted for late Q4 2026 subject to shareholder and regulatory approvals. (Link)
  32. Footbridge Partners and ALZA Capital Partners sold Ohio-, Pennsylvania- and Michigan-based medical spa platform The Skin Center to an undisclosed middle-market healthcare private equity fund. Footbridge Partners and ALZA Capital Partners exited The Skin Center, a medical spa and cosmetic surgery platform operating 14 locations across Pennsylvania, Ohio and Michigan, selling to an unnamed middle-market healthcare private equity fund in a recapitalization. Terms were undisclosed. Founded in 1981 by Jerry and Dominic Brandy, the company delivers neurotoxins, dermal fillers, laser skin resurfacing, laser hair removal and cosmetic surgery under CEO Eric Warden. Footbridge co-founder and Managing Partner David Rosner credited management and providers for the outcome. The incoming sponsor inherits a platform positioned for de novo openings and further M&A across the consolidating medical aesthetics market. (Link)

Venture Deals and Other

  1. MannKind Corporation (NASD: MNKD) raised approximately $50 million in a private placement led by Frazier Life Sciences. MannKind (NASD: MNKD) closed a roughly $50 million private placement with institutional investors, led by longstanding biotech investor Frazier Life Sciences. The company sold 10,440,838 common shares at $3.89 and pre-funded warrants for 2,412,632 shares at $3.88, with a $0.01 exercise price and no expiry. Proceeds fund general corporate purposes including a $45 million contingent value rights payment triggered by the FDA’s July 23, 2026 approval of Furoscix ReadyFlow for edema in heart failure and chronic kidney disease patients. (Link)
  2. Insight Partners led a $19 million Series A in AI-native provider credentialing platform Assured, with participation from First Round Capital and Kindred Ventures. Insight Partners led Assured’s $19 million Series A, joined by existing backers First Round Capital and Kindred Ventures, bringing total capital raised to $25 million following a $6 million seed in September 2025. Insight Managing Director Teddie Wardi articulated the thesis directly: incumbent credentialing tools function as systems of record while Assured’s agents perform the work itself, verifying data against more than 2,000 primary sources and cutting credentialing time by 30%. Launched in 2024, the NCQA-certified CVO serves over 100 organizations including Houston Methodist. Proceeds expand R&D and go-to-market teams ahead of a privileging product in early 2027. (Link)
  3. Brevy Care raised $4.77 million with participation from GreyMatter Capital to expand Medicaid reimbursement software for family caregivers. Brevy Care, a developer of software helping family caregivers access Medicaid reimbursements, raised $4.77 million in a round including San Francisco-based GreyMatter Capital, a mental and behavioral health-focused venture firm founded in 2021 that typically writes first checks of $250,000 to $1.2 million. The financing brings Brevy’s total capital raised to $4.92 million. GreyMatter’s thesis centers on early-stage innovation in behavioral healthcare delivery and adjacent care-navigation infrastructure. For investors, Brevy addresses a reimbursement-access gap in self-directed Medicaid programs, a payer-funded and demographically supported category as aging populations shift care burden toward unpaid family members. (Link)
  4. Sixth Street Growth led a $120 million Series D in autonomous revenue cycle management platform Candid Health, with participation from Oak HC/FT, 8VC and Y Combinator. Candid Health raised $120 million led by Sixth Street Growth, the dedicated growth platform of Sixth Street, which manages over $135 billion and has invested more than $13 billion across 90-plus companies. Oak HC/FT, 8VC and Y Combinator participated. The round marks a 3x valuation increase over the February 2025 Series C led by Oak HC/FT. Managing Director Alex Katz cited diligence calls with nearly 40 customers and proof points applying agentic AI at scale. Candid reported 190% year-over-year annual contracted run-rate growth and 180% net dollar retention in 2025, targeting the $280 billion US RCM spend. (Link)
  5. Innovation Endeavors and Xora co-led a $21 million Series A in sensor developer Elio, with participation from Kevin Weil, Scribble VC, UpWest and Resolute Ventures. Elio, a Silicon Valley and Israel-based company building sensors designed for artificial intelligence rather than human vision, raised $21 million co-led by Innovation Endeavors and Xora. Kevin Weil and Scribble VC participated, alongside existing investors UpWest and Resolute Ventures, who led the prior round. Total funding reaches $29 million. Founded by former Meta AR/VR executives, Elio embeds computation directly into optics using dynamic micromirror layers that behave like a neural network, letting AI decide what to capture in real time. Investors are backing applications spanning microscopy, semiconductor inspection, robotics and defense drone detection. (Link)
  6. 7wire Ventures and Allumia Ventures co-led an oversubscribed $16.2 million Series A in Karoo Health, joined by First Trust Capital Partners, SpringRock Ventures and Hyde Park Angels. Karoo Health, an Albuquerque, New Mexico cardiovascular technology company led by CEO Ian Koons, closed a $16.2 million oversubscribed Series A co-led by 7wire Ventures and Allumia Ventures, with First Trust Capital Partners, SpringRock Ventures and Hyde Park Angels participating. Managing Partners Lee Shapiro of 7wire and Jeff Stolte of Allumia join the board. Deployed programs have produced independently analyzed reductions exceeding 40% in emergency department visits and inpatient admissions, plus a greater than 10% total cost of care reduction. Karoo supports 600-plus cardiology providers across 11 states; proceeds fund predictive models and health plan expansion. (Link)
  7. FUSE led a $16 million financing in AI-powered concierge primary care platform Prosper Medical, with participation from Aurum Partners, Better.vc, Cal Innovation Fund, Fluent, Latitude Capital, Knoll Ventures and WTI. Prosper Medical, a San Francisco company founded in 2026 by CEO Ryan McQuaid and CMO James Wantuck, MD, raised $16 million led by FUSE alongside Aurum Partners, Better.vc, Cal Innovation Fund, Fluent, Latitude Capital, Knoll Ventures and Western Technology Investment. Investors are backing repeat founders who previously built PlushCare and sold it to Accolade for $450 million. Unlike cash-pay concierge peers, Prosper is in-network with major insurance plans across all 50 states at a $69 monthly membership, using an AI care layer for longitudinal data aggregation and referral coordination. Proceeds expand the physician network and enter new markets. (Link)
  8. Decathlon Capital Partners provided a non-dilutive growth-debt investment to value-based care technology company Health Endeavors. Decathlon Capital Partners, a growth-debt provider with offices in Palo Alto and Park City, made a strategic investment in Health Endeavors, a Farmington, Utah technology partner to Accountable Care Organizations. Deal size was undisclosed, but the structure requires no dilution of existing shareholders. Managing Director Matt Hoffman framed the investment as conviction in value-based care economics. Health Endeavors serves over 2 million patients with 16-plus years of ACO experience and partnerships with Novant Health and Providence. Decathlon targets companies with $4 million to $100 million revenue, 10%-plus growth and near-term visibility to cash-flow-positive status, avoiding equity dilution and loss of control. (Link)
  9. Vensana Capital and Ohio-based Mutual Capital Partners co-led a $30 million Series A in TYBR Health, with participation from Neovate Capital Partners and existing investors. TYBR Health, a Houston, Texas orthopedic biologics company co-founded and led by CEO Tim Keane, PhD, raised $30 million in Series A financing co-led by Vensana Capital and Mutual Capital Partners, the Cleveland, Ohio venture firm managed by Bill Trainor and Wayne Wallace that invests exclusively in Midwest healthcare IT and medical device companies. Proceeds expand commercial access to the FDA-cleared B3 GEL System, a flowable extracellular matrix hydrogel, broaden indications and fund clinical studies on tissue protection during orthopedic surgery. (Link)

CLICK HERE to sign up
for all news and updates